Analysis of urinary concentrations of calcium phosphate crystal- associated proteins: α2-HS-glycoprotein, prothrombin F1, and osteopontin

Journal of the American Society of Nephrology

Volumn 10, Issue SUPPL. 14, 1999, Pages

  Nishio, Shunji ^a   Hatanaka, Masayuki ^a   Takeda, Hajime ^a   Iseda, Tokuhiro ^a   Iwata, Hidenobu ^a   Yokoyama, Masayoshi ^a  

^a EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM PHOSPHATE; GLYCOPROTEIN; GLYCOPROTEIN ALPHA2 HS; OSTEOPONTIN; PROTHROMBIN; PROTHROMBIN F1; UNCLASSIFIED DRUG;

ADULT; CALCIUM STONE; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; CRYSTALLIZATION; ENZYME IMMUNOASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; NEPHROLITHIASIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN URINE LEVEL; URINARY EXCRETION;

EID: 0032748902     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (16)

1. Iwata H, Iseda T, Nishio S, Takeuchi M: Normal human urine and calcium oxalate stone matrix contain prothrombin and its degradation products. In: Urolithiasis, edited by Pak CYC, Resnick MI, Preminger GM, Dallas, TX, Millet the Printer, 1996, pp 556-557
2. Iseda T, Iwata H, Nishio S, Takeuchi M: α2-HS-glycoprotein, prothrombin activation peptide and osteopontin are three major proteins associated with urinary calcium phosphate crystals [Abstract]. J Urol 155: 1332, 1996
3. Nishio S, Takeda H, Iseda T, Yokoyama M, Iwata H, Takeuchi M: Inhibitory effects of α2-HS-glycoprotein, prothrombin and osteopontin on calcium oxalate crystallization [Abstract]. J Urol 159: 1240, 1998
4. Stapleton AMF, Seymour AE, Brenman JS, Doyle IR, Marshall VR, Ryall RL: The immunohistochemical distribution and quantification of crystal matrix protein. Kidney Int 44: 817-824, 1993
5. Stapleton AMF, Dawson CJ, Grover PK, Hohmann A, Comacchio R, Boswarva V, Tang Y, Ryall RL: Further evidence linking urolithiasis and blood coagulation: Urinary prothrombin fragment 1 is present in stone matrix. Kidney Int 49: 880-888, 1996
6. Kohri K, Nomura S, Kitamura Y, Nagata T, Yoshioka K, Iguchi M, Yamate T, Umekawa T, Suzuki Y, Sinohara H, Kurita T: Structure and expression of the mRNA encoding urinary stone protein (osteopontin). J Biol Chem 268: 15180-15184, 1993
7. McKee MD, Nanci A, Khan SR: Ultrastructural immunodetection of osteopontin and osteocalcin as major matrix components of renal calculi. J Bone Miner Res 10: 1913-1929, 1995
8. Yamate T, Umekawa T, Iguchi M, Kurita T, Kohri K: Detection of osteopontin as matrix protein in calcium-containing urinary stones. Acta Urol Jpn 43: 623-627, 1997
9. Atmani F, Glenton PA, Khan SR: Identification of proteins extracted from calcium oxalate and calcium phosphate crystals induced in the urine of healthy and stone forming subjects. Urol Res 26: 201-207, 1998
10. Kleinman JG, Beshensky A, Worcester EM, Brown D: Expression of osteopontin, a urinary inhibitor of stone mineral crystal growth, in rat kidney. Kidney Int 47: 1585-1596, 1995
11. Doyle IR, Marshall VR, Dawson CJ, Ryall RL: Calcium oxalate crystal matrix extract: The most potent macromolecular inhibitor of crystal growth and aggregation yet tested in undiluted human urine in vitro. Urol Res 23: 53-62, 1995
12. Ryall RL, Grover P, Stapleton AMF, Barrell DK, Tang Y, Moritz RL, Simpson RJ: The urinary F1 activation peptide of human prothrombin is a potent inhibitor of calcium oxalate crystallization in undiluted urine in vitro. Clin Sci 89: 533-541, 1995
13. Worcester EM, Blumenthal SS, Beshensky AM, Lewand D: The calcium oxalate crystal growth inhibitor protein produced by mouse kidney cortical cells in culture is osteopontin. J Bone Miner Res 1: 1029-1036, 1992
14. Dickson IR, Bagga M, Paterson CR: Variations in the serum concentration and urine excretion of α2-HS-glycoprotein, a bone-related protein, in normal individuals and in patients with osteogenesis imperfecta. Calcif Tissue Int 35: 16-20, 1983
15. Bezeaud A, Guillin MC: Quantitation of prothrombin activation products in human urine. Br J Haematol 58: 597-606, 1984
16. Min W, Shiraga H, Chalko C, Goldfarb S, Krishna GG, Hoyer JR: Quantitative studies of human urinary excretion of uropontin. Kidney Int 53: 189-193, 1998